IPO pricing and investor demand will determine initial market capitalization; monitor overallotment exercise (up to 3.75M additional shares) and Regeneron's concurrent investment at a discount. The substantial cash runway reduces near-term financing risk and supports pipeline advancement through key clinical milestones.
Executive Summary
Parabilis Medicines, a clinical-stage biopharmaceutical company developing Helicon therapeutics for undruggable targets, filed Amendment No. 2 to its S-1 registration statement, setting an IPO price range of $17.00-$19.00 per share for 25,000,000 shares. Concurrently, Regeneron will invest $75.0 million in a private placement at 90% of the IPO price, complementing a $50.0 million upfront from a May 2026 collaboration. Proceeds will fund clinical development of lead candidate zolucatetide in desmoid tumors and other indications, advance preclinical pipeline, and support general operations, extending cash runway into H2 2029.
Key Financial Metrics
Key Facts
- IPO of 25,000,000 shares at $17.00-$19.00 per share; total estimated net proceeds of $413.6 million (midpoint).
- Regeneron committed to $75.0 million private placement at 90% of IPO price (4,629,629 shares at $18.00 midpoint).
- Recent $50.0 million upfront from Regeneron collaboration for Antibody-Helicon Conjugates.
- Lead candidate zolucatetide showed 74% ORR in desmoid tumors; Phase 3 registrational trial expected H1 2027.
- Cash and equivalents of $329.0 million as of March 31, 2026; pro forma as-adjusted cash of $826.0 million post-offering.
- Net loss of $145.9 million in 2025 and $45.3 million in Q1 2026; accumulated deficit of $586.8 million.
Financial Impact
IPO proceeds of approximately $413.6 million (net) from offering plus $75.0 million from Regeneron private placement, totaling $488.6 million in new capital (midpoint).
Risk Factors
- Pre-revenue, clinical-stage company with no approved products and history of operating losses.
- Reliance on novel Helicon platform; clinical and regulatory risks for zolucatetide and pipeline candidates.
- Significant dilution from this offering and future capital needs.
- Competition from established therapies and other novel modalities targeting Wnt/b-catenin pathway.
- Dependence on Regeneron collaboration and sole-source manufacturers.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-256398 |
| Document: ck0001657677-ex10_3.htm | 0001193125-26-256398 |
| Document: ck0001657677-ex1_1.htm | 0001193125-26-256398 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers